These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 23472268)

  • 21. The direction of end-stage renal disease reimbursement in the United States.
    Lockridge RS
    Semin Dial; 2004; 17(2):125-30. PubMed ID: 15043614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic corrections and the potential impact on the dialysis industry.
    Sullivan JD
    Nephrol News Issues; 2009 Jul; 23(8):14-6. PubMed ID: 19662907
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost effectiveness of IDPN therapy measured by hospitalizations and length of stay.
    Cranford W
    Nephrol News Issues; 1998 Sep; 12(9):33-5, 37-9. PubMed ID: 9923295
    [No Abstract]   [Full Text] [Related]  

  • 24. Medicare program; end-stage renal disease prospective payment system, quality incentive program, and bad debt reductions for all Medicare providers. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2012 Nov; 77(218):67450-531. PubMed ID: 23139948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cost of clinical dialysis--a historical perspective.
    Attrill E; Johnson HK
    Semin Nephrol; 2000 Nov; 20(6):523-5. PubMed ID: 11111853
    [No Abstract]   [Full Text] [Related]  

  • 26. Does MFD fit under Medicare coverage?
    Robers S
    Nephrol News Issues; 2001 May; 15(6):52-3, 55. PubMed ID: 12109003
    [No Abstract]   [Full Text] [Related]  

  • 27. KI study: older patients with CKD are costly as they transition to dialysis.
    St Peter W
    Nephrol News Issues; 2004 Oct; 18(11):85. PubMed ID: 15551617
    [No Abstract]   [Full Text] [Related]  

  • 28. Finances of the independent dialysis facility.
    DeOreo PB
    Blood Purif; 2007; 25(1):7-11. PubMed ID: 17170530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reimbursement rates and quality of care in the dialysis industry: a policy discussion.
    Kaserman DL
    Issues Law Med; 1992; 8(1):81-102. PubMed ID: 1624272
    [No Abstract]   [Full Text] [Related]  

  • 30. Accountable care organizations and ESRD: the time has come.
    Nissenson AR; Maddux FW; Velez RL; Mayne TJ; Parks J
    Am J Kidney Dis; 2012 May; 59(5):724-33. PubMed ID: 22459132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and cost of ESRD therapy.
    Am J Kidney Dis; 1991 Nov; 18(5 Suppl 2):21-9. PubMed ID: 1951354
    [No Abstract]   [Full Text] [Related]  

  • 32. Quality, access, and costs: public policy and home health care.
    Harrington C
    Nurs Outlook; 1988; 36(4):164-6. PubMed ID: 3290859
    [No Abstract]   [Full Text] [Related]  

  • 33. Who should be paying for vitamin D analogues--Medicare or the patients?
    Hall G
    Nephrol Nurs J; 2006; 33(3):345-6, 351. PubMed ID: 16859205
    [No Abstract]   [Full Text] [Related]  

  • 34. Palliative dialysis in end-stage renal disease.
    Trivedi DD
    Am J Hosp Palliat Care; 2011 Dec; 28(8):539-42. PubMed ID: 21398269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The politics of health cost containment: end-stage renal disease.
    Rettig RA
    Bull N Y Acad Med; 1980; 56(1):115-38. PubMed ID: 6986928
    [No Abstract]   [Full Text] [Related]  

  • 36. The medical directorship of renal dialysis facilities under the new Medicare conditions for coverage: challenges and opportunities.
    DeOreo PB
    Blood Purif; 2009; 27(1):16-21. PubMed ID: 19169012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medicare program; end-stage renal disease quality incentive program. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2011 Jan; 76(3):627-46. PubMed ID: 21261127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The costs of dialysis in the USA.
    Garella S
    Nephrol Dial Transplant; 1997; 12 Suppl 1():10-21. PubMed ID: 9075223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Squeezing the inner-city dialysis dollar.
    Kanter A
    Nephrol News Issues; 1989 Nov; 3(11):24-6. PubMed ID: 2594108
    [No Abstract]   [Full Text] [Related]  

  • 40. The success of medicare's end-stage renal-disease program: the case for profits and the private marketplace.
    Lowrie EG; Hampers CL
    N Engl J Med; 1981 Aug; 305(8):434-8. PubMed ID: 7019710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.